The vitamin D-binding protein, also known as groupspecific component (Gc) or Gc-globulin, is a 51.2-kDa polymorphic protein of the ␣ 2 -macroglobulin fraction of human plasma (1 ) . In human population, three common alleles (Gc1f, Gc1s, and Gc2) and Ͼ120 rare variant alleles have been classified by isoelectric focusing (2 ) . Gc1f and Gc1s contain sialic acid residues, whereas Gc2 does not (2 ) . Gc-globulin may have an important role in the activation of macrophages and in osteoclast differentiation from monocytes and thus may control bone morphogenesis and remodeling (3) (4) (5) (6) (7) . In humans, deglycosylation of Gc-globulin, involving stepwise removal of ␤-galactose and sialic acid from the trisaccharide, leaving N-acetyl-galactosamine (GalNAc), produces a potent macrophage-activating factor (Gc-MAF) (3 ) . GalNAc is considered to have a crucial role in the macrophageactivating and osteoclast-differentiating functions of Gc-MAF because the removal of this sugar has been shown to be associated with the loss or impaired function of macrophages (8, 9 ) . In osteopetrotic rat and mice models (6, 7 ) and in a single human study (4 ) , indirect data suggested a defect in lysophospholipid-inducible Gc-MAF, although direct estimation of this factor in healthy and diseased states has not been performed.
Gc-MAF estimation has been hampered by the lack of a suitable detection system for determining the sterically exposed GalNAc, which is critical for the activating properties of Gc-MAF. Because no standard preparation of Gc-MAF (as opposed to Gc-globulin) is available, its presence must be inferred from its properties. We here describe a hybrid sandwich lectin-ELISA for the measurement of the sterically exposed GalNAc (10, 11 ) generated in vitro from Gc-globulin in the plasma of healthy subjects.
Blood was collected from 11 healthy subjects by venipuncture into EDTA sample tubes, and the plasma was separated within 5 min by centrifugation at 300g for 5 min at room temperature (25°C). The buffy coat layer, containing Ͼ70% lymphocytes, was carefully removed under sterile conditions with a Pasteur pipette, excluding red cells as far as possible, and layered into a plastic Petri dish (60 ϫ 15 mm). Plasma (5 mL) was transferred to the Petri dish containing the buffy coat cells, and 0.3 mol/L CaCl 2 was added to the plasma sample to obtain a final ionized calcium concentration of 1.5 mmol/L. [Ca 2ϩ ] was determined by ion-selective electrode. Lymphocyte confluence was confirmed under a phase contrast microscope. The plasma-white cell preparations were then incubated in 5% CO 2 at 37°C; samples (0.4 mL) were removed at 0, 4, 8, and 16 h and centrifuged, and the supernatants were stored at 4°C for assay. The study was approved by the local Ethics Committee in accordance with the current revision of the Helsinki Declaration, and all subjects gave their written informed consent.
Microtiter plates were prepared for assay by coating with 0.1 mL (1:400 dilution of goat anti-human polyclonal Gc-globulin antiserum) containing ϳ3.5 g of IgG (Diasorin) in 0.1 mol/L bicarbonate buffer (composed of 4.24 g/L Na 2 CO 3 and 5.04 g/L NaHCO 3 , pH 9.6) and incubating overnight at 4°C. The antiserum was then tipped away, and the unoccupied binding sites on the wells were blocked by washing six times with a solution containing 1 mL/L Tween-20, 0.1 mol/L phosphate buffer, 3.32 g/L Na 2 HPO 4 , and 0.57 g/L NaH 2 PO 4 , pH 7.4. The plate was then slapped dry over absorbent paper and used for the assay. Incubated plasma samples (0.1 mL) were then added to wells and incubated for 4 h at 4°C. The samples were then tipped away, the wells were washed six times with Tween-20 solution in phosphate buffer, and the plate was slapped dry. We added 0.1 mL of horseradish peroxidase (HRP)-labeled Helix pomatia lectin (25 ng; SigmaAldrich) in 0.1 mol/L Tris-HCl buffer, pH 7.4, containing 1 mmol/L MnCl 2 to the wells and incubated the plates for 1 h at room temperature. The solution was then tipped away, and the wells were washed six times with Tween-20 solution as above and slapped dry. 3,3Ј-5,5Ј-Tetramethylbenzidine (TMB; 0.1 mL; Bionostics) was added to the wells and incubated at room temperature for 10 min. The absorbance was then measured at 620 nm on a Multiskan MCC 340 plate reader (Labsystems). In the absence of any standard preparation of Gc-MAF, it was not possible to express the absolute concentration of the factor; therefore, the concentration is expressed in terms of absorbance produced by capture of HRP-labeled lectin. H. pomatia lectin, composed of six subunits and with a molecular mass of 79 kDa, possesses particularly high specificity for terminal N-acetyl-␣-d-galactosaminyl residues (12 ) . The association constant between GalNAc and H. pomatia lectin is of the same order of magnitude as for other carbohydrate-anticarbohydrate systems, including antibodies and other lectins (12 ) . Each assay was carried out in triplicate, and appropriate controls (plasma sample without white blood cells and 5 mol/L GalNAc) were treated in parallel.
The intraassay precision of the lectin sandwich assay was determined using 30 replicates of a plasma-white cell preparation incubated for 16 h. In the absence of a standard preparation of Gc-MAF, an indirect estimation of Gc-MAF was carried out. To estimate the activity of HRP-labeled lectin, a defined quantity of the lectin (100 L of 0.1, 0.5, 1, and 2 g/L) was added to microtiter plates. The plates were incubated with TMB at room temperature for 10 min, and the absorbance produced by the enzyme reaction was determined. The reaction conditions, such as temperature, pH, and buffer composition, were kept similar throughout the experiments, and the lectin binding to microtiter plate was assumed to be 90% in all experiments (13 ) . For the purpose of making an Technical Briefs estimation of the sensitivity of detection of Gc-MAF, the stoichiometry of the antibody:Gc-MAF:lectin interaction was assumed to be 1:1:1.
Gc-globulin in plasma was measured by an established RIA using the monospecific polyclonal antibody (Diasorin) and Gc-globulin (Calbiochem Novabiochem) (10 ) . The intraassay precision of the RIA was tested by measuring 20 replicate samples diluted at a concentration of 600 mg/L, 16 replicates of a sample at 400 mg/L, and 12 replicate samples at 200 mg/L; the CVs were 6.9%, 8.1%, and 8.6%, respectively. The plasma Gc-globulin concentrations (range, 250 -470; mean Ϯ SD, 350 Ϯ 53 mg/L) have been reported previously (9 ) and were within previously described limits (200 -500 mg/L) (14, 15 ) .
The Gc-MAF assay was specific because excess GalNAc (5 mol/L) totally blocked binding of the lectin (Fig. 1A) . This indicates that there is a negligible amount of nonspecific binding of lectin to the matrix and that most of it specifically binds to GalNAc in Gc-MAF captured by the Gc-globulin antibodies. Because B-and T-cell surface membrane-bound glycosidases are crucial for the generation of Gc-MAF, in the absence of white blood cells no generation of Gc-MAF from Gc globulin is expected. Thus, when plasma was incubated without white blood cells, Gc-MAF was not generated (Fig. 1B) .
The presence of lymphocyte-enriched buffy coat in the plasma-white cell incubations was associated with a linear generation of Gc-MAF in all subjects, and the omission of lymphocytes from the incubations was associated with failure of in vitro Gc-MAF generation. All control subjects showed basal noninduced generation of Gc-MAF when their lymphocytes were incubated with the plasma Gcglobulin. The rates of Gc-MAF generation varied among 11 male controls; the CV for the increase in absorbance after 16 h was 42%. The generation of activating factor was constant over the first 8 h, with a slight decline thereafter.
The detection limit of the method was assessed approximately from the change in absorbance for various concentrations of lectin-enzyme complex under routine conditions with the assumptions stated above and was compared with the change in absorbance detected during assays. From these experiments, the detection limit of the assay was estimated (mean zero absorbance ϩ 2.5 SD) to be Ͻ2 pmol/L. The generation of Gc-MAF from Gcglobulin is achieved by the action of the B-and Tlymphocyte membrane-bound ␤-galactosidase and neuraminidase, respectively (4 ) . Because the circulating plasma concentrations of Gc-globulin are known to be relatively high, the activities of the glycosidases are likely to determine the rate of Gc-MAF generation.
It has been reported that Gc-MAF generation was detected indirectly only after induction by lysophosphatidylcholine, a mediator of inflammation (5, 6 ) ; however, we observed Gc-MAF generation even in the absence of a mediator of inflammation. Indeed, our method has shown continuous Gc-MAF generation in plasma from healthy adults and the absence of production in a patient with recessive osteopetrosis, but with production demonstrated posttransplantation, coincident with clinical and molecular genetic evidence of engraftment and bone remodeling (9 ) .
The rate of increase in Gc-MAF in the in vitro incubations was estimated to be ϳ30 fmol ⅐ L Ϫ1 ⅐ min Ϫ1 (calculation is based on the fact that 0.1 pmol of HRP-labeled lectin per microtiter well incubated for 1 min produced an absorbance of 0.35; in Gc-MAF assays, 16 h incubation of 0.1 mL of plasma from a healthy adult produced an absorbance of 0.096). Because the lymphocyte-enriched white blood cell preparations used in these experiments were at 10-fold higher concentrations than in circulating (A), Gc-MAF generation in plasma samples of a young male adult incubated with lymphocytes and then either treated or not treated with excess GalNAc (5 mol/L). (B), Gc-MAF generation in plasma samples incubated with or without lymphocytes from a 60-year-old healthy male subject. The change in absorbance at 620 nm (⌬Absorbance 620 nm) corresponds to the change in the concentration of Gc-MAF.
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blood, we estimate that the rate of generation in vivo is likely to be ϳ3 fmol ⅐ L Ϫ1 ⅐ min Ϫ1 . The blood concentrations of Gc-MAF thus are likely to be quite low; therefore; it is unlikely to act as an endocrine factor. In view of its expected increased generation at sites of inflammation, because of the presence of a large number of T-and B-lymphocytes, it is much more likely to act similarly to a paracrine or autocrine agent.
No in vivo or in vitro assays for Gc-MAF have been reported. The current approach in which Gc-MAF generated by lymphocyte enrichment is then demonstrated by lectin-ELISA may enable investigation into the physiology and pathology of this important compound and its effects on bone remodeling. Endogenous anabolic steroids and their precursors in the form of dietary supplements have become widely available as over-the-counter tablets in the United States or through the Internet in other countries.
Dehydroepiandrosterone (DHEA) is an endogenous steroid produced by the ovaries and adrenal glands. As a precursor to testosterone and estrogen, DHEA can be converted peripherally to androstenedione, testosterone, and dihydrotestosterone, and aromatized to estrogen. Recently, athletes have begun taking DHEA, theoretically hoping to derive some competitive benefit from its conversion to testosterone. However, in a few subjects (1, 2 ), no effect of DHEA on body weight, body mass, resting metabolic rate, total energy expenditure, or proteolysis was demonstrated. Late in 1996, the International Olympic Committee (IOC) Medical Commission added DHEA to the list of prohibited compounds.
In a study performed by Dehennin et al. (3 ) , labeled DHEA was converted to testosterone, and therefore, some questions were received by our laboratory from sports federations concerning the potential increase of the urinary testosterone/epitestosterone ratio (T/E) through DHEA supplementation. According to Bosy et al. (4 ) , the urinary T/E ratio is only slightly affected for a short period of time (2-5 h), without exceeding 6:1, the current acceptable ratio for the IOC. In their study, seven male volunteers ingested a daily DHEA dose of 50 mg each morning for 30 days. Urine specimens were collected before ingestion and 2-3 h after ingestion. Their urinary baseline T/E ratios were 0.1-1.2. The authors reported that individual postdose T/E ratios ranged from 0.01 to 3.7, as measured each day.
In opposition, in a study by Bowers (5 ) , a 47-year-old subject, with a predose urinary T/E ratio of 2.4, who received single 50-, 100-, or 150-mg doses of DHEA for 4 days at breakfast had a T/E ratio Ͼ6:1 for all three doses on day 3, tested on a 24-h sample. The actual T/E ratios were 8.1, 11.4, and 14.4, which can be indicative of exposure to exogenous steroids.
In the current study, we investigated the concentrations of DHEA and testosterone in hair from three subjects who received DHEA for 30 days. Hair is a cumulative specimen that has been demonstrated to document chronic exposure, acting as an historical record.
Although not yet recognized by the IOC, hair has demonstrated useful applications in forensic and clinical toxicology.
Three male subjects (30, 38, and 46 years of age; urinary T/E Ͻ2) took DHEA (Natrol) at breakfast for 30 consecutive days as a single dose of 25 mg (tablet). A strand of hair was collected before the DHEA was administered to 414 Technical Briefs determine basal DHEA and testosterone concentrations; another strand was collected 10 days (the time at which the hair emerges from the skin) after the last DHEA dose to determine drug accumulation. Both testosterone and DHEA were analyzed by gas chromatography coupled to mass spectrometry according to our published procedure (6 ) . In each case, a 1-cm section from the root of the hair was analyzed, roughly corresponding to 1 month of hair growth.
Briefly, 100 mg of hair was incubated for 15 min at 95°C in 1 mL of 1 mol/L NaOH in the presence of 1 ng of testosterone-d 3 , used as the internal standard. After cooling, the homogenate was neutralized with 1 mL of 1 mol/L HCl, and 2 mL of 0.2 mol/L phosphate buffer (pH 7.0) was added.
The drugs were extracted by solid-phase extraction. The Isolute C 18 columns were conditioned with 3 mL of methanol, followed by 2 mL of deionized water. After sample addition, the columns were washed twice with 1 mL of deionized water. After column drying, analyte elution occurred with the addition of two 0.75-mL aliquots of methanol. The eluant was evaporated to dryness under nitrogen at 40°C, and the residue was reconstituted in 1 mL of 0.2 mol/L phosphate buffer (pH 7.0). A further purification step was achieved by addition of 100 mg of Na 2 CO 3 /NaHCO 3 (1:10, by weight) and 2 mL of pentane. After agitation and centrifugation, the organic phase was removed and evaporated to dryness. The residue was derivatized by the addition of 50 L of N-methyl-Ntrimethylsilyltrifluoroacetamide/NH 4 I/2-mercaptoethanol (1000:2:5, by volume), and then incubated for 20 min at 60°C.
A 4-L aliquot of the derivatized extract was injected into the column of a Hewlett Packard gas chromatograph (6890 Series) via a Hewlett Packard (model 7673) autosampler. The flow of carrier gas (helium; purity grade N55) through the column (HP5-MS capillary column; 5% phenyl-95% methylsiloxane; 30 m ϫ 0.25 mm i.d.; 0.25-mm film thickness) was 1.0 mL/min. The injector temperature was 270°C, and splitless injection was used with a split valve off-time of 1.0 min, using the pulsed mode. The column oven temperature was programmed to rise from an initial temperature of 150°C, maintained for 1 min, to 295°C at 30°C/min, and was maintained at 295°C for the final 8 min. The detector was a Hewlett Packard 5973 operated in the electron impact mode. The electron multiplier voltage was set at 600 V above the electron impact-tune voltage.
Linearity was observed in the range 1-50 pg/mg for both testosterone and DHEA. The relative extraction recoveries were 91.6% and 92.2% for DHEA and testosterone, respectively. The limit of detection was 0.5 pg/mg for both compounds. The within-run imprecision (CV) was 12% for DHEA (at 6.6 pg/mg) and 6.6% for testosterone (at 3.8 pg/mg), respectively (6 ) .
The measured concentrations are reported in Table 1 . The basal concentrations in hair were within the physiological ranges we reported previously (6 ) for both DHEA (1.2-6.7 pg/mg) and testosterone (0.5-9.8 pg/mg). After 30 days of daily DHEA supplementation, the incorporation of DHEA into the hair was obvious, with large interindividual variation, probably because of differences in hair pigmentation. On the other hand, no increase in the testosterone concentration in hair was observed. In this case, DHEA supplementation did not produce increased concentrations of testosterone in hair.
Melanins are responsible for the color of hair, as determined by the quantity of pheomelanin and eumelanin present in hair. Black and brown hair contain more eumelanin than red and blond hair. Current evidence suggests that melanin is the principal component in the binding of drugs in hair. Several studies performed with animals and humans reported that organic compounds are excreted preferentially in dark hair and suggested that excretion of drug is closely linked to the presence of melanin (7 ) . Our studies suggest that hair color or melanin content may be the major determinant of DHEA binding, and consequently, may produce color bias in hair testing for DHEA.
In conclusion, this study may be interpreted as a useful adjunct to the characterization of DHEA abuse because the drug is easily incorporated into hair. The findings that the testosterone concentration is not increased in hair after repetitive administration of DHEA should not impact the urinary results. (1, 2 ) . Serum PTHrP is increased in 47-100% of HM patients (3) (4) (5) (6) and in almost all patients with HHM. In up to two-thirds of hypercalcemic patients with bone metastases, serum PTHrP is increased (5, 7 ) . PTHrP assays may aid in the diagnosis of HHM (8 ) .
IRMAs that measure large N-terminal regions appear to be optimal for HM evaluation (9 ) . With the first commercially available IRMA (Nichols Institute), PTHrP concentrations were found to be increased in 40 of 81 (49%) HM patients. Moreover, healthy subjects had detectable values up to 2.6 pmol/L (10 ), contrary to some reports (5, 8, 11 ) . With an IRMA from Mitsubishi Petrochemical Co (12 ), PTHrP was increased in all 46 studied patients with hypercalcemia and solid tumors, and most healthy subjects had values Ͻ1 pmol/L. However, almost all patients had HHM, and the specificity toward normocalcemic cancer (C.NoCa) patients was not thoroughly investigated.
We have evaluated a commercially available PTHrP IRMA. We particularly studied the assay specificity for HM patients compared with normocalcemic patients presenting an active cancer, with patients in complete remission from their cancer, and with patients suffering from osteopenia, osteoporosis, or chronic renal failure (CRF).
The first control group included 94 patients (88 women and 6 men), median age 61 years (range, 26 -80 years), referred to our bone clinic for a low bone mass or established osteoporosis. The patients were classified (13 ) as follows: 39 osteopenic (T score at the lumbar spine of Ϫ1.78 Ϯ 0.09, mean Ϯ SE); 29 osteoporotic (T score Ϫ3.16 Ϯ 0.10); 26 established osteoporosis (low bone mass and presence of one or more fragility fractures). The second control group included 31 patients in end-stage CRF. The third control group included 62 patients (56 women and 6 men), median age 57 years (range, 36 -80 years), in complete remission from malignancies for a median of 5 years (range, 2-22 years). The tumors included breast (n ϭ 47), cervix (n ϭ 3), Hodgkin lymphomas (n ϭ 3), head and neck (n ϭ 2), prostate (n ϭ 2), thyroid (n ϭ 2), and 3 miscellaneous (1 endometrium, 1 ovary, and 1 pituitary). The fourth control group included 85 normocalcemic cancer patients (74 women and 9 men), median age 62 years (range, 33-89 years; C.NoCa group).
The tumors included breast (n ϭ 65), lung (n ϭ 5), prostate (n ϭ 5), cervix (n ϭ 3), endometrium (n ϭ 3), and 4 miscellaneous (1 head and neck, 1 stomach, 1 bladder, and 1 soft tissue sarcoma). Bone metastases were definite in 74 (extensive in 66), absent in 8, and doubtful in 3 patients (14 ) .
The HM group included 38 patients (18 women and 20 men), median age 57 years (range, 26 -85 years), recruited consecutively. They were studied before any specific hypocalcemic therapy; 5 were treated by radiotherapy and 15 by chemo-or hormonotherapy at the time of evaluation. The tumors included breast (n ϭ 12), head and neck (n ϭ 8), lung (n ϭ 4), and 14 miscellaneous (3 of unknown origin, 2 bladder, 2 vulva, 1 melanoma, 1 rectum, 1 cervix, 1 esophagus, 1 gallbladder, 1 teratocarcinoma, and 1 sarcoma). Twenty patients had epidermoid tumors, 15 had adenocarcinomas, and 3 had other histologies. Bone metastases were definite in 19 (extensive in 12), absent in 18, and doubtful in 1. Mean (Ϯ SE) serum calcium (corrected for protein) was 3.37 Ϯ 0.07 mmol/L (13.5 Ϯ 0.3 mg/dL); the median was 3.24 mmol/L (range, 2.62-5.24 mmol/L). PTH was adequately suppressed at 6.3 Ϯ 0.6 ng/L; the median was 4.5 ng/L (range 4.0 -17.2 ng/L) (15 ) .
PTHrP was measured (IRMA of DiaSorin Corp., Stillwater, MN) with human recombinant PTHrP 1-84 for calibrators and controls. Calibrators were supplied lyophilized and were reconstituted in PTHrP-free human serum (zero calibrator). The method for the IRMA is as follows. Anti-PTHrP 1-40 antibody is bound to polystyrene beads, and an anti-PTHrP 57-80 antibody is labeled with 125 I. Samples are incubated sequentially with the antibodies, and the polystyrene beads are then washed. The remaining radioactivity is measured.
Blood was collected into EDTA-coated tubes containing aprotinin at 1000 kallikrein inhibitor units/mL blood (16 ), put on ice immediately after collection, and separated within 60 min; the plasma was stored at Ϫ20°C for Ͻ6 months.
As described previously (9, 14, 15 ) , blood markers included total serum calcium (reference interval or "normal values", 2.12-2.57 mmol/L), calcium corrected for protein concentrations ( 
mmol/L)] (19 ).
Data are expressed as the mean Ϯ SE and/or by the median (range) when indicated. We performed classical tests (ANOVA, 2 , and nonparametric correlations) with
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Technical Briefs Statview TM II (Abacus Concepts) and the log-rank test for survival analysis with Statistica TM 4 (Statsoft). The detection limit (mean ϩ 3 SD of 20 determinations of the zero calibrator) was 0.3 pmol/L. Results were considered reportable only when they were greater than the first calibrator (1 pmol/L). The within-run imprecision (CV) was 4.0%, 3.3%, and 3.4% at PTHrP concentrations of 3.3, 12.5, and 92 pmol/L (n ϭ 20). Interassay CVs (n ϭ 11) were 8.8%, 5.2%, and 3.8% at 3.4, 12.8 and 96 pmol/L. Dilution curves from plasma samples containing high endogenous PTHrP concentrations (four patients with HM) were parallel to the calibration curve. Recovery of 5-100 pmol/L PTHrP 1-84 from three PTHrP-free serum samples was 83-100% (93% Ϯ 3%). Although all of our clinical samples were collected into aprotinin-containing tubes, we have started to determine the need for protease inhibitors. EDTA-whole blood samples from 10 healthy donors were supplemented with 30 pmol/L PTHrP 1-84 and stored for up to 4 h at room temperature with or without aprotinin (400 kIU/mL). The recovery was 98%, suggesting that protease inhibitors may not be necessary for samples stabilization.
Values were unreportable in 124 healthy subjects (Ͻ1 pmol/L). PTHrP was also unreportable in all 94 patients of the osteoporotic group and in all 31 patients with CRF, was reportable in only 1 of 62 (2%) patients in complete remission from cancer, in 4 of 85 (5%) patients in the C.NoCa group, and was increased (reportable) in 31 of 38 (82%) cancer patients with HM ( Fig. 1 ). In patients with HM, mean PTHrP concentrations were 7.4 Ϯ 1.1 pmol/L; the median value was 6.0 pmol/L (range, Ͻ1-26.5 pmol/ L). PTHrP was increased in all 20 patients with epidermoid tumors and in 10 of 15 (67%) patients with adenocarcinomas. PTHrP was increased in all 18 patients without bone metastases and in 12 of 19 (63%) patients with bone metastases. Mean PTHrP thus was higher in patients without bone metastases, 9.6 Ϯ 1.3 pmol/L, than in patients with bone metastases, 5.2 Ϯ 1.6 pmol/L (P Ͻ0.05).
Baseline values of the biochemical markers in patients with HM are summarized in Table 1 . Patients were divided according to the presence (n ϭ 31) or the absence (n ϭ 7) of increased PTHrP. Patients with increased PTHrP had lower osteocalcin, P i , and TmP/GFR. Their survival was also shorter than patients with PTHrP concentrations within the reference interval (log-rank test, P Values in brackets indicate the numbers of unreportable results (Ͻ1 pmol/L). Osteop., osteopenia or osteoporosis; CRF., chronic renal failure; CR., cancer in complete remission; C.NoCa., normocalcemic patients with an active cancer; HM., hypercalcemia of malignancy, divided according to tumor histology, epidermoid (Epid.), adenocarcinomas (Adeno.), and miscellaneous (Other). In patients with HM, correlations were significant between PTHrP and P i (r s ϭ Ϫ0.52; P Ͻ0.01), TmP/GFR (r s ϭ Ϫ0.51; P Ͻ0.01), and TRCaI (r s ϭ 0.38; P Ͻ0.05). Correlations between PTHrP and Ca 2ϩ or calcium corrected for protein concentrations were significant in the group of patients without bone metastases (r s ϭ 0.53-0.54; P Ͻ0.05).
The technical validation demonstrates that this assay is robust and reproducible, and that it satisfies the criteria of recovery and linearity. From a clinical point of view, the data indicate that it is highly sensitive (82% of increased values in patients with HM) and specific for HM (specificity of 95% in patients with an active cancer, 99% in patients in remission from cancer, and 100% in patients with benign diseases or healthy subjects). It appears to be at least as sensitive and specific as in-house assays (2, 5, 11, 20 ) and more so than other commercial IRMAs (10, 12 ) . Moreover, this IRMA is the first commercial assay able to demonstrate the pathological relevance of circulating PTHrP concentrations: we observed expected correlations between PTHrP and P i , TmP/GFR and TRCaI, corresponding to the well-known effects of PTHrP on phosphate and calcium tubular reabsorption (21) (22) (23) .
In patients with HM, PTHrP was increased in 100% of the patients with epidermoid tumors, whether or not they had bone metastases. PTHrP was increased in 67% of patients with adenocarcinomas and in 58% of patients with breast cancer and bone metastases. These findings confirm and expand the original work of Grill et al. (5 ) and indicate that, in addition to tumor-derived locally produced bone-resorbing factors, hypercalcemia of breast cancer can be attributable to paraneoplastic secretion of PTHrP, just as is classically observed in HHM.
This study was supported in part by grants from Fondation Medic, Fonds National de la Recherche Scientifique (Belgium, Contract FRSM 3.4577.96 and Télévie Contract 7.4509.97), and Fondation Lambeau-Marteau. We thank Dr. MacFarlane (DiaSorin) for assistance in providing the most recent data, and DiaSorin for the gift of the PTHrP assay kits. However, free thyroxine (FT 4 ) measurements remain useful to confirm the diagnosis of thyroid diseases and to evaluate the thyroidal status when TSH measurements appear to disagree with the clinical picture, as may be the case in patients with nonthyroidal illnesses (1 ) .
Intermethod Discordant Free Thyroxine
Because it represents only a minute fraction of the total serum T 4 , measuring FT 4 , i.e., T 4 not bound to binding proteins, remains difficult. This is especially true for sera from patients with nonthyroidal illnesses that have an altered binding capacity (2, 3 ) . A variety of in vitro methods have been developed to estimate FT 4 . The lowmolecular weight radioactive-labeled analog method was much criticized (2 ) and was soon completely withdrawn from the market. The most widely used methods are now the two-step assay and the one-step labeled-antibody assay. The aim of our study was to compare FT 4 concentrations in sera from patients with nonthyroidal illnesses, measured with three recent nonisotopic automated techniques and with three manual RIAs: two immunoextraction assays (one two-step and one one-step assay), and a direct equilibrium dialysis (ED) assay considered as the reference method (2 ) .
The patient panel consisted of 20 hospitalized subjects on the seventh day following a bone marrow transplant, an example of severe acute illness. The bone marrow transplant was indicated for several hemopathies (n ϭ 12) or solid cancers (n ϭ 8). All patients were euthyroid before the treatment, and none had been known to have a patent thyroid dysfunction in the past. The preparation regimen before the transplant consisted of chemotherapy alone (n ϭ 11) or chemotherapy associated with total-body radiotherapy (n ϭ 9). After the transplant (allogenic in 9 cases and autogenic in 11 cases), patients received immunosuppressive drugs such as glucocorticosteroids (prednisone, 10 -20 mg/day), cyclosporin, methotrexate, and calcium folinate. They also received granulocyte growth factors, antibiotics, antiviral and antifungal drugs, low-molecular weight heparinate (1000 -10 000 units/day), and several comfort medications. All of the procedures we followed were in accordance with the Helsinki Declaration of 1975 and the subsequent 1996 amendments. The patient sera were collected for routine analysis, were kept frozen at Ϫ20°C, and were analyzed shortly after thawing.
Two automated FT 4 methods were labeled-antibody immunoassays: the electrochemiluminescent Elecsys FT 4 assay from Roche Diagnostics performed on the 2010 analyzer; and the enhanced chemiluminescent Vitros ECI FT 4 assay from Ortho-Clinical Diagnostics. The third automated assay was a non-isotope-labeled analog technique: ADVIA Centaur FrT4 from Bayer Diagnostics. The two-step RIA was the GammaCoat FT 4 from DiaSorin, and the one-step RIA was the labeled antibody kit Amerlex-MAB FT 4 4 values have been plotted as the percentage of the mean reference value, determined in the laboratory from Ͼ100 euthyroid control subjects (Fig. 1) . The TSH results obtained with the four methods were in close agreement. When a low threshold of 0.15 mIU/L was used, only one sample (patient 11) was intermethod discordant, with borderline results between 0.12 and 0.17 mIU/L. All other TSH results obtained with the four assays were concordant, yielding 8 values within the reference interval and 11 decreased values. This finding confirms the good reliability of recent TSH assays, which, as in our previous study (4 ) , classified the sera in an equivalent way. However, the Vitros ECI TSH median was lower than the three others (Wilcoxon paired-rank test, P Ͻ0.07), and as already reported with the Immulite and AxSYM TSH assays (5 ), a negative bias between the Vitros ECI TSH results and the Elecsys, Immulite, and ADVIA Centaur TSH results was observed at low values Ͻ0.2 mIU/L.
The FT 4 value obtained with the ED technique was within the reference interval in 11 sera and increased in 9. To study the agreement between the FT 4 results obtained with the different assays and with the dialysis technique, the percentages of concordance were calculated and the degree of concordance was measured using Cohen's kappa coefficient () (6 ) . For this purpose, FT 4 results were classified as low, normal, or high, using the reference limits of each assay. As generally accepted, concordance was judged to be very good for Ͼ0.80 and good for 0.81 Ͼ Ͼ 0.60 (7 ) .
FT 4 concordance with the dialysis method was good and very good for the Vitros ECI FT 4 and the GammaCoat FT 4 , respectively (Table 1) . It was poor and not statistically significant for the Elecsys FT 4 , and there was no concordance at all ( Ͻ0) for the ADVIA Centaur and Amerlex-MAB FT 4 assays.
The dialysis method represents a fundamentally reliable approach for FT 4 measurements, although it causes a dilution (1:13 in the Nichols kit); the effect of this dilution on FT 4 determinations is difficult to assess if binding competitors are present (2 ) . The transplanted patients were heparin treated. Heparin is known to induce, in vivo, a release of lipoprotein lipase from the vascular endothelium. The lipolytic activity of this enzyme in vivo, and/or in vitro during sample storage and assay, leads to an increase in the serum concentration of nonesterified free fatty acids (NEFAs), which are binding competitors of T 4 , and consequently to an increase in FT 4 (8 ) . The production of NEFAs is negligible during storage at Ϫ20°C, but it could be particularly marked during the overnight dialysis step at 37°C. Like ED, the GammaCoat assay is based on a sound physicochemical basis, and it has been shown to give values in close agreement with those of ED in many states, such as high and low binding
protein concentrations, autoantibodies, low total T 4 , and nonthyroidal illness (9 ) . Against ED, the GammaCoat assay has the advantage of involving a much shorter incubation time at 37°C (20 min instead of 16 h), which should limit the generation of NEFAs in vitro. Increased FT 4 results were also frequent with the GammaCoat assay: eight results were above the upper reference limit. Therefore, increased ED FT 4 values should not be considered an in vitro artifact resulting from prolonged dialysis at 37°C, but they may be a reflection of in vivo hyperthyroxinemia.
Among the other four FT 4 assays, only the Vitros ECI showed an acceptable concordance with ED results. This new labeled-antibody assay, like ED, has been shown to be free of biases that depend on the serum binding capacity and does not include albumin in the assay reagents to buffer the effects of NEFAs (10 ) . The other two labeled-antibody assays, the Elecsys and Amerlex-MAB, include albumin in their reagents. Albumin can induce negative biases when the serum binding capacity is reduced, as it is in sera from patients with nonthyroidal illnesses (10 ) . The ADVIA Centaur FT 4 reagents do not contain albumin. The negative bias observed with this method might be related to the sensitivity of the labeled analog to variations in serum albumin concentrations. The ADVIA Centaur analog is a high-molecular weight analog, IgG-T 4 complex labeled with acridinium ester. In general, macromolecular analogs are not considered albumin-dependent, and they do not have the marked drawbacks of low-molecular weight radioactive analogs (11 ) . However, it has been shown that, contrary to the Vitros ECI, the Chiron ACS:180 FT 4 
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Technical Briefs when a competitor such as furosemide was added to serum (13 ) . Our results are consistent with the sensitivity of the ADVIA Centaur assay to the serum binding capacity. The dependence on the serum binding capacity of the ADVIA Centaur kit, the Amerlex-MAB kit, and to a lesser extent the Elecsys kit, may also explain the decreased FT 4 measurements observed with these three kits: the number of FT 4 results below the lower limit of the reference interval for each kit were three, four, and one, respectively. TSH results were frequently decreased, and FT 4 values obtained with the ED technique, GammaCoat, and Vitros ECI kits were frequently increased. However, the concordance between the Elecsys TSH results, chosen as example, and FT 4 determined with these three kits was poor: the percentages of concordance were between 60% and 65%; and the coefficient, lying between 0.24 and 0.33, was not statistically significant ( Table 1 ). The concordance was still lower with Elecsys FT 4 and absent ( Ͻ0) with the ADVIA Centaur and the Amerlex-MAB FT 4 . The relationship between serum TSH and FT 4 has been well characterized in individuals with normal hypothalamic and pituitary functions and stable concentrations of thyroid hormones. The poor degree of agreement between the FT 4 and TSH values in our study might be attributable in part to transient hyperthyroxinemia that did not last long enough to induce a decrease in TSH to Ͻ0.15 mIU/L. Transient hyperthyroxinemia may lead to high FT 4 concentrations with TSH concentrations within the reference interval. One reason for the discordant low TSH values in the presence of FT 4 values within the reference interval may be related to the glucocorticoid treatment in these patients, which decreases TSH secretion and lowers serum TSH concentration without decreasing FT 4 below the lower limit of the reference interval (14 ) . Finally, the discordance between TSH values within the reference interval and decreased FT 4 values may be attributed to the negative bias of the Amerlex-MAB, ADVIA Centaur, and Elecsys FT 4 assays. This bias might be related to decreased serum binding capacity. The poor concordance we observed between TSH and FT 4 might also be related to the impairment of the hypothalamic pituitary thyroid axis in a critical situation such as bone marrow transplant.
In conclusion, despite a negative bias of the Vitros ECI TSH at concentrations Ͻ0.2 mIU/L, the concordance between all TSH methods was good in bone marrowtransplanted patients. The FT 4 concentrations measured with recent automated methods were not equivalent. Among the three automated methods studied, which may gain widespread use, only the Vitros ECI showed a good concordance with the ED and GammaCoat kits, which frequently gave increased values and which are known to be technically reliable assays (2, 9 ) . However, patients with nonthyroidal illnesses, such as those of this study, are not considered as hyperthyroid but as presenting with euthyroid sick syndrome (15 ). They do not benefit from treatment directed at normalizing FT 4 . FT 4 results within the reference intervals were obtained in 85% of the patients with the Elecsys assay and in 80% of the patients with the ADVIA Centaur and Amerlex-MAB assays. If the "quality" of a FT 4 method, in this situation, is judged on a "to treat or not to treat" basis, FT 4 assay methods that more frequently produce values within the reference intervals, such as the Elecsys, ADVIA Centaur, and Amerlex-MAB, should be preferred. More than ever it is necessary to have a good knowledge of the FT 4 method used to correctly interpret the results of thyroid function tests in patients with nonthyroidal illnesses. This work was supported by the Hô pitaux Universitaires de Strasbourg. We thank Bayer Diagnostics and OrthoClinical Diagnostics for providing their TSH and FT 4 reagents free of charge. We also thank N. Heider for carefully reviewing the English in the manuscript. (1, 2 ) . Plasma 5-HT is derived largely from the enteroendocrine cell in the gastrointestinal tract. The evidence of the relationships between 5-HT and these pathological conditions has been obtained mostly from studies of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) in the plasma of humans (3 ). The most reliable laboratory test to detect a carcinoid tumor is the repeated determination of the urinary 5-HIAA (4 ). In addition, wholeblood 5-HT is increased in patients with metastatic midgut carcinoid tumors (1, 2 ) .
Liquid chromatography with electrochemical detection provides the highest sensitivity for the determination of human plasma 5-HT and/or 5-HIAA. However, widely variable "normal" concentrations of plasma 5-HT (0.5-44 g/L) have been reported (5) (6) (7) (8) (9) (10) . These inconsistencies might be attributable to variations in assay techniques or calibration or the release of 5-HT from platelets during sample preparation. In our previous study, we successfully assayed human plasma 5-HT by ultrafiltration and microbore liquid chromatography-electrochemical detection (10 ) . The objective of this study was to apply this pretreatment procedure to the measurement of plasma 5-HT and 5-HIAA in healthy subjects and cancer patients.
Blood samples from 165 healthy subjects (65 women and 100 men; age range, 25-79 years) and from 40 cancer patients (21 women and 19 men; age range, 25-76 years) were collected and centrifuged immediately to separate plasma (1000g for 20 min at 4°C). Informed consent was obtained from each person before this study. Of those patients specified as having intestinal cancers, 8 had gastric cancers and 17 had colon cancers. Two patients with early cancers (limited within submucosal layer) and 11 patients with advanced cancers received excision of the primary tumor and lymph node dissection. Twelve patients were considered unresectable because of invasion to vital organs or distant metastasis; these patients received either palliative or bypass surgery. Patients with carcinoid tumors were excluded from this study.
The liquid chromatography system was composed of a Beckman 126 pump (flow rate, 50 L/min), a BAS-4C amperometric detector (set at ϩ0.75 V; Bioanalytical Systems), and a microbore column (Inertsil-2, 5-m octadecylsilane, 100 ϫ 1.0 mm; G.L. Sciences) (10 ) . The mobile phase consisted of 75 mL of acetonitrile, 5 mL of tetrahydrofuran, 2.2 mmol/L sodium 1-octanesulfonate, 14.7 mmol/L monosodium dihydrogen orthophosphate, 30 mmol/L sodium citrate, 0.027 mmol/L EDTA, and 1 mL of triethylamine in 1 liter of doubly distilled water (adjusted to pH 3.5). Plasma 5-HT and 5-HIAA were calculated by determining each peak-area ratio relative to the internal standard, 3-methoxytyramine. Statistical evaluation was performed using unpaired Student t-tests, and P Ͻ0.05 was accepted as significant.
Plasma 5-HT and 5-HIAA concentrations in the 165 healthy individuals were 0.62 Ϯ 0.11 and 1.94 Ϯ 0.09 g/L (mean Ϯ SE), respectively ( Table 1 ). The plasma 5-HT concentrations (6.26 Ϯ 1.59 g/L) in cancer patients (both intestinal cancer and hepatoma; n ϭ 40) were significantly higher (P Ͻ0.05) when compared with healthy subjects. The plasma 5-HT concentrations of patients with intestinal cancer (n ϭ 25) were significantly higher (6.96 Ϯ 2.26 g/L) when compared with healthy subjects. Lembeck (11 ) reported increased plasma 5-HT in a patient with carcinoid tumor. The secretion rate of 5-HT by a carcinoid tumor could exceed the maximum uptake capacity of platelets, leading to increased plasma 5-HT (12, 13 ) . Thus, the 5-HT produced by the tumor might first occupy all available binding sites on platelets before circulating as free plasma 5-HT. However, the 5-HT concentrations decreased dramatically to 1.96 Ϯ 0.78 g/L after surgery to remove cancer cells from patients with intestinal cancer (n ϭ 13). Our data suggested that removing these cancer cells from patients might limit the production of circulating 5-HT. The plasma 5-HIAA concentrations did not change significantly after surgery in the above intestinal cancer patients. However, Page et al. (14 ) demonstrated Both amplification and T m analysis are performed on the same fluorescence-detection thermocycler, the GeneAmp 5700 Sequence Detection System (PE Biosystems). The single-tube assay uses a specific primer set, with a high annealing temperature, and a fluorescent dye that can detect double-stranded DNA product. Because the temperature at which double-stranded templates dissociate depends largely on product length, GC content, and sequence structure, the PCR product has a distinct T m , depending on base substitutions, single point mutations, or insertions/deletions.
Soon after the last amplification cycle, the reaction is slowly cooled by 1°C steps from 95°C to 60°C. Detection follows this cooling process, with the related SYBR green emissions reflecting the amplicon renaturation kinetics. Analysis of the resulting melting profiles allows determination of insertions and, hence, of the corresponding genotype of the genomic template.
The most consistent feature of Gilbert syndrome is a deficiency in bilirubin glucuronidation. The UGT1A gene is responsible for bilirubin catalytic enzyme production. The lower expression of the UGT1A gene is related to a TA insertion in the TATA box of the gene promoter (5 ). The resulting PCR product differs from the wild-type gene in having a two-base insertion. This T m analysis of PCR products allowed discrimination between the wildtype, homozygous, and heterozygous samples in an Italian family.
The PCR was performed as follows. To a final volume of 50 L were added 1ϫ SYBR Green I Buffer (Molecular Probes); 5.5 mmol/L MgCl 2 ; 200 mol/L each dATP, dGTP, and dCTP; 400 mol/L dUTP, 5 U of AmpliTaq Gold ® ; 1 U of AmpErase uracil-N-glycosylase; 50 ng of genomic DNA; 50 nmol/L of the forward primer (5Ј-ATTAACTTGGTGTATCGATTGGTTT-3Ј); and 300 nmol/L of the reverse primer (5Ј-CAGCAGGCCCAGGACAA-3Ј. All reagents were purchased from PE Biosystems. The cycling conditions were as follows: 40 cycles of 50°C for 2 min, 95°C for 10 min, 94°C for 15 s, and 60°C for 1 min.
At the end of PCR, the dissociation protocol included a slow cooling from 95°C to 60°C in 20 min. During this time, the fluorescence was measured every 3 s, for a total of 400 data points. The reaction was performed on the 5700 Sequence Detection System equipped with the 5700 Sequence Detection System software. This application makes it possible to follow the melting profile for each amplicon; the software calculates the first derivative of the profile, making it possible to highlight the point at which the reassociation occurs (see Fig. 1 ).
More than 15 samples were run in quadruplicate and in different PCR runs. Unaffected DNA coming from unrelated subjects was used for the wild-type control samples.
Clinical Chemistry
To confirm the results, PCR products were sequenced or separated on 10% acrylamide gels.
The key to optimizing this assay is to minimize nonspecific amplification and primer-dimer formation. An effective hot start is provided here by the use of dUTP and uracil-N-glycosylase in the PCR. Although intended as a means of controlling carryover contamination from previously amplified DNA, the use of uracil-N-glycosylase and dUTP means that nonspecific primer extensions containing dU are cleaved up until the enzyme is heatinactivated (6 ). This together with a "chemical" hot start given by the AmpliTaq Gold reduces the risk of primerdimer formation.
For typing the UGT1A TATA box, 50 ng of genomic DNA was sufficient, and a primer optimization matrix was run in quadruplicate, using final concentrations of 50 and 300 mmol/L for each primer. No-template controls were run in the same assay to verify nonspecific PCR product formation. All of the tested 50/300, 50/50, and 300/50 (mmol/L) forward/reverse primer combinations did not give any nonspecific products. No fluorescence was detected up to the end of PCR (threshold cycle Ͼ40), whereas in the presence of target DNA, the PCR product was detectable after 27, 34, and 30 cycles, respectively. Lower cycle thresholds are related to a higher sensitivity of the test; the 50/300 (mmol/L) primer combination was chosen for this reason.
The 5700 Sequence Detection System allows "real-time PCR" (7, 8 ) by analyzing product formation cycle by cycle, thus allowing us to confirm the correct amount of starting genomic DNA. At the end of the reaction, the melting profile analysis was performed on the instrument. The melting profile of each sample was followed every 3 s; the first derivative at the flex point gave the right melting peak for each sample (9 ) . To evaluate this experiment, each sample was run four times in the same PCR, and in three different PCR runs. The resulting T m profiles are shown in Fig. 1 .
This study presents an analysis of Gilbert syndrome in an Italian family: ϳ15 subjects from the same family were studied. The patient was a daughter born of consanguineous parents; together with the daughter and her parents, samples from all relatives were submitted to analysis. The coefficient of variation was calculated to validate the T m test analysis; it ranged from 0.2% to 0.06%, thus allowing us to state that the tests were reproducible and reliable. Together with each sample studied, an unrelated wildtype control DNA was used in the same conditions.
The wild-type control and the homozygous patients (daughter and father) presented a clearly distinguishable difference in T m (85.4 and 86.7°C, respectively). Several samples analyzed were heterozygous for a TA insertion; it was also possible to discriminate such samples because they showed T m peaks with values between those of the wild-type and the mutant samples.
All PCR products were run on a 10% acrylamide gel to confirm the presence of insertions in both homozygous and heterozygous samples. The PCR reactions were also sequenced on an a ABI 310 (PE Biosystems) platform to confirm the T m analysis pattern.
This newly developed technique allows screening of genomic variations such as single-nucleotide polymorphisms (9 ) and insertions.
Gilbert syndrome affects 6 -12% of the population. This disease is often related to a TA insertion in the TATA box promoter of the UGT1A gene; affected heterozygous individuals present little or no visible manifestation, whereas homozygous subjects show mild jaundice and insufficient bilirubin clearance (5 ). To date, these kinds of analysis have been performed with different techniques such as sequencing, single-strand conformation polymorphism, and polyacrylamide gel electrophoresis of PCR products.
This technology is a suitable alternative to the standard PCR-single-strand conformation polymorphism method because it is straightforward and easier to perform, requires less DNA, is less time-consuming, and gives a good degree of automation compared with the need of pouring a gel for electrophoresis. We have developed an easy and inexpensive method of determining genotypes of doublebase insertions that is not dependent on fluorescent probes and without post-PCR processing. This kind of wt, wild-type control (green) with its relative T m value on the x axis; het, heterozygous profile (blue); mut, mutant profile (father and daughter; red).
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Technical Briefs analysis is a very reliable test because it is reproducible and able to distinguish between wild-type and mutant samples, whether homozygous or heterozygous. The reproducibility of the method allowed us to test several subjects. All of the samples were successfully and unambiguously genotyped; the T m genotyping study was confirmed either by sequence or by polyacrylamide gel electrophoresis.
For further applications (i.e., single point mutations) this kind of genotyping assay would be an interesting method. The melting curve analysis is related to DNA sequence, GC content, and PCR product length (short amplicons are strongly preferred for reliable calling); taking such points into account, it should be easy to set up and perform other screening applications where, of course, a sequencing approach could always confirm the T m profile. Single-nucleotide polymorphisms have been identified by many different experimental approaches. The human ␤-globin gene has been genotyped by several methods, including PCR followed by restriction digestion (1, 2 ) , denaturing gradient gel electrophoresis (3 ), allele-specific amplification during PCR, and the ligase chain reaction (4 ). These methods require several hours and sometimes days for diagnosis. Recently, rapid-cycle PCR has been combined with real-time fluorescence monitoring to detect mutations by fluorescent probe melting point analysis for homogeneous genotyping in Ͻ1 h. Fluorescent melting point analysis is a technique that detects mutations by differences in the melting temperature (T m ) of fluorescent oligonucleotides hybridized to different alleles (5) (6) (7) . Probes of a single color are usually used for genotyping. Four alleles at two different loci have been genotyped by multiplexing probe T m s of a single color (8 ) . However, there is a limit to how many alleles can be distinguished by differences in T m . The ability to use multiple colored probes along with T m would greatly extend the power of monitoring PCR with fluorescence by allowing greater numbers of loci to be screened for mutations in one reaction. Exon 1 of the ␤-globin gene has Ͼ50 mutations, which produce various hemoglobinopathies (9 ) . Hemoglobins S, C, and E are common and are routinely screened. Hemoglobin C (Hb C) results from a G-to-A mutation in the first nucleotide of codon 6, whereas hemoglobin S (Hb S) arises from an A-to-T mutation in the second nucleotide of this codon. Hemoglobin E (Hb E) results from a G-to-A mutation in the first nucleotide of codon 26. The close proximity of these three mutations allowed us to design a probe system that discriminated all genotypes using T m and two probe colors.
Rapid ␤-Globin
The human ␤-globin gene sequence (GenBank accession no. U01317) was used to design primers and probes for the amplification of a 214-bp segment containing exon 1 (Fig. 1a) . Because of the high homology between the ␤-globin and ␦-globin sequences, the primers (sense, 5Ј-GTCAGGGCAGAGCCATCTA-3Ј; antisense, 5Ј-GTTC-TATTGGTCTCCTTAAAGGTG-3Ј) were designed with 3Ј and additional mismatches to ␦-globin. In addition, because of the close proximity of the hemoglobin mutations, a unique combination of probes was designed to detect Hb S, C, and E alleles. Fig. 1b shows the melting peaks for homozygous Hb C (T m ϭ 50.9°C; SD ϭ 0.48°C; n ϭ 8). The C-trait has both the Hb C and wild-type peaks. The genotype of a compound heterozygote, Hb S/C, is shown in Fig. 1b , panel C, along with the corresponding Hb C and Hb S genotypes. Genotyping of the Hb E allele is shown in fig. 1b , panel D. Single melting peaks are shown for homozygous Hb E (T m ϭ 66.1°C; SD ϭ 0.13°C; n ϭ 3) and wild-type (T m ϭ 57.1°C; SD ϭ 0.20°C; n ϭ 52) genotypes, whereas the E-trait has two melting peaks corresponding to each allele. The codon 6 and codon 26 probes discriminated the 10 most common hemoglobin genotypes in exon 1. Homozygous samples for the wild type (codon 6, n ϭ 21; codon 26, n ϭ 50), Hb S (n ϭ 1), Hb C (n ϭ 2), and Hb E (n ϭ 1) as well as S-trait (n ϭ 23), C-trait (n ϭ 5), E-trait (n ϭ 2), and the compound heterozygotes Hb S/E (n ϭ 1), C/E (n ϭ 1), and S/C (n ϭ 1) were correctly genotyped. The codon 6 probe sequence that showed the best resolution between the wild-type, Hb S, and Hb C alleles was completely matched to the Hb S allele. Probes that matched either the wild-type or Hb C alleles did not resolve all genotypes as effectively. The total time for amplification and genotyping of 32 samples was Ͻ1 h.
Probe melting temperature is dependent on external factors (salt concentration and pH) and intrinsic factors (concentration, duplex length, GC content, and nearest neighbor interactions) (11) (12) (13) (14) . Mismatches between the oligonucleotide probe and DNA target cause a decrease in the T m of the duplex (15, 16 ) . By designing a probe specific to a mutation locus, genotyping by melting curve analysis in real time is possible. Each allele has a characteristic T m , and multiple alleles can be identified by a single probe. Depending on the type of mismatch, varying degrees of destabilization occur. Mismatches that are relatively stable, e.g., G-T mismatches, have T m shifts of 2-3°C (7 ), whereas less stable C-A mismatches have 8 -10°C T m shifts (6, 8 ) . The mismatch position and the number of mismatches also affect T m and can be used to enhance polymorphism discrimination (16 ) . Single-color hybridization probes can identify multiple mutations under a probe and detect unexpected polymorphisms. The cystic fibrosis F508del locus was genotyped recently by melting curve analysis with hybridization probes (17 ) . A 10°C T m shift was observed between the wild-type and the F508del alleles. Unexpectedly, some samples showed aberrant 5°C T m shifts. This unique T m was correlated to the F508C allele with a single T-C mismatch to the probe. Subtle changes in T m can also indicate unexpected polymorphisms. A probe to the factor V locus revealed two additional mutations sites characterized by differences in T m as small as 0.8°C (18 ) . Because a single probe can characterize multiple alleles, we designed a single hybridization probe to cover the adjacent single base changes in exon 1 of the hemoglobin gene that produce Hb C and Hb S. Additional alterations in the sequence under the probes, such as Hb Leiden (deletion of codon 6 and/or 7) or Hb Chesterfield (codon 28 CTG3 CGG), should also be detectable (9 ) .
Multiple hybridization probes can also be used for multiplex genotyping of loci that are not in close proximity. Multiplexed hybridization probes of the same color have identified four different hemochromatosis alleles and a fifth unexpected variant (8 ) . Two probe pairs each identified two expected alleles with characteristic T m s. The T m of the unexpected variant was within 1.5°C of a mutant allele. Although the T m s of the five alleles were discernible in this case, unexpected mutations can cause genotyping errors if allele T m s overlap. Although the number of distinct T m s that can be differentiated is limited, different colors can be used to increase the extent of multiplexing. For example, hybridization probes have been used to detect apolipoprotein E mutations at the ⑀2/⑀3 and ⑀3/⑀4 loci with LC Red 640 and LC Red 705 dyes, respectively (19 ) .
Other methods have been developed to detect polymorphisms with oligonucleotide probes. TaqMan TM probes (20, 21 ) and molecular beacons (22 ) can be used to correlate a single fluorescent probe to a specific allele. In these cases, the number of different detectable mutations is limited to the number of colors available. Although not performed in real time (21 ) , the TaqMan system has been used to genotype three different point mutations simultaneously by using seven different colored probes (one for
background correction). By multiplexing the probe T m s and only two colors, we were similarly able to genotype three different point mutations. An additional advantage of using hybridization probes is that unexpected sequence alterations can be detected.
The ability to multiplex PCR analysis by color and T m has many uses in addition to multiplex genotyping. For example, internal amplification controls often are needed for infectious disease and translocation testing to verify that amplifiable DNA or cDNA is present even if the target amplification is negative. Another common need is for multiplexing a competitor as an internal standard for PCR quantification.
This work was financially supported by an STTR grant from NIH (GM-58983). We thank Alex Chagovetz, Christine Litwin, and Elaine Lyon for insightful conversation, and Doug Searles for probe synthesis. The clinical spectrum of acute pancreatitis (AP) ranges from mild, self-limiting symptoms to a fulminating, rapidly lethal disease. Early objective identification of the risk of major complications or death is essential for appropriate management of individual patients and for the efficacy of treatment. However, clinical judgment alone is of low sensitivity in predicting severity and outcome in AP (1 ), and clinicobiochemical criteria such as those of Ranson (2 ) and Blamey et al. (3 ) suffer from a lack of simplicity and a 48-h delay in final assessment. Radiological methods enable a reliable diagnosis of necrotizing pancreatitis, but their availability often is limited (4 ). Several newer single-factor markers have been described as being effective in identifying severe AP. The acute phase reactant, C-reactive protein (CRP), is a most useful single marker that is cheap and easy to measure, but it also requires 48 h for maximal response (5, 6 ) .
Procalcitonin Is Not a Reliable
Recently, procalcitonin (PCT), a 116-amino acid propeptide (M r 13 000) of calcitonin with a long half-life in the systemic circulation, was found in high concentrations in patients with severe bacterial or fungal infections and sepsis (7 ) , and it was reported as a marker in assessing the infection of necrotizing pancreatitis in late-stage disease (8 ) and in evaluating the biliary origin of the AP (9 ) . In contrast to the classical acute-phase protein CRP, PCT is not increased after operative trauma (10 ) . The aim of this study was to examine the ability of PCT to provide early prediction of severity and to assess the etiology of AP and in addition examine the relationship between PCT and the acute phase protein, CRP.
We studied 31 consecutive patients with AP (14 males
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Technical Briefs and 17 females; mean age, 66.4 years; range, 34 -87 years), with onset of pain Ͻ24 h before admission. We measured serum PCT and CRP within the first 24 h after admission. The diagnosis of AP was based on typical clinical symptoms associated with at least a twofold increase in serum lipase, and was confirmed by abdominal ultrasonography and/or contrast-enhanced computed tomography. In 25 patients, pancreatitis was of biliary origin (defined by one or more of the following criteria: increased cholestasis laboratory parameters, history of gallstones, and presence of dilated common bile duct and biliary sludge and/or stones by ultrasonography and/or contrast enhanced computed tomography and/or endoscopic retrograde cholangiography). In the six other patients, the pancreatitis was attributable to alcohol abuse in one and of unknown origin in five. The severity of pancreatitis was assessed on the basis of the Atlanta criteria (11 ) , which are largely used to assess a posteriori the severity of AP. In brief, these criteria define AP as mild if local and/or systemic complications are absent or are present with only minimal organ dysfunction; the pancreatitis is defined as severe if local complications (necrosis, pseudocysts, or abscess) and/or one or more organ dysfunctions are present. According to the Atlanta criteria, the pancreatitis was mild in 19 patients and severe in 12.
The 31 healthy subjects included in the present study were in general good health, free from medication, and without clinical or laboratory signs of hepatic, biliary, renal, intestinal, or endocrinological malfunction.
After study participants gave informed consent, blood samples were taken on admission and then daily for 5 days. All serum samples were stored at Ϫ20°C until assayed. All samples were analyzed in duplicate within 6 months of collection. PCT was measured by a manual procedure with an immunoluminometric assay (12 ) (LUMI test PCT; Brahms Diagnostica GmbH) that requires ϳ180 min to perform. Serum CRP was determined using a nephelometric technique (CRP; Dade Behring). The inter-and intraassay analytical imprecision (CV) for the two markers was as follows: 11% and 19% for PCT (mean, 0.62 g/L), and 2.7% and 4.9% for CRP (mean, 4.8 mg/L), respectively. The upper reference limits reported Boxes illustrate the 25th and 75th percentiles; the lines inside the boxes represent the median value; whiskers are extended to the smallest and largest observations in a group that are Ͻ1.5 box-lengths from the box. E indicates values Ͼ1.5 box-lengths but Ͻ3 interquartile ranges from the end of the box (outlier values). P values, patients with severe AP vs patients with mild AP. in the package inserts for PCT and CRP were 0.5 g/L and 5.0 mg/L, respectively. All statistical evaluations were performed with the SPSS/PCϩ statistical package on a personal computer. The data were not gaussian distributed; therefore, a nonparametric test was used. During the first 6 days, the concentrations of CRP and PCT in the patients with pancreatitis were significantly higher than those in healthy subjects (P Ͻ0.001, MannWhitney U-test). As shown in Fig. 1 , the peak for both CRP and PCT in the severe group was observed at the 3-day time point. PCT in the mild group was not significantly different from that in the severe group at any point in the study, whereas the CRP was significantly lower in the mild group than in the severe group on days 2-6. The values of all samples obtained from the 31 patients were pooled and used for the calculation of the best cutoff for the two markers. Receiver-operating curves in differentiating between severe and mild disease showed that CRP had a larger area under the curve than did PCT (0.776 Ϯ 0.026 vs 0.456 Ϯ 0.036; P Ͻ0.001) (13, 14 ) . The cutoff value, with maximal likelihood ratios (15 ), was 0.252-0.255 g/L for serum PCT and 128 -129 mg/L for serum CRP. (These cutoff values represent the range in which the likelihood ratio did not change.) The sensitivity and specificity of the two markers at these cutoffs in assessing the severe form of AP for the entire period are reported in Table 1 . No significant differences in PCT or CRP were found between patients with biliary and nonbiliary AP.
Our data confirm that CRP is a good marker of severity in later stages of AP. PCT has been proposed as a marker for the noninvasive, accurate prediction of infected necrosis as well as for the selection of patients with persisting septic complications after surgical debridement (8 ) . In our population, PCT serum concentrations were similar in patients with severe AP and in those with the mild form of the disease. The absence of a significant difference is in accordance with the clinical course of patients who did not develop infectious complications. In fact, only 1 of our 12 patients with severe pancreatitis underwent pancreatic surgery because of infected necrosis; he died on the fifth day. Even this patient's serum PCT was lower than the upper reference limit.
In conclusion, our data indicate that CRP is better than serum PCT in assessing in severity of AP. However, we cannot exclude that PCT could be useful in detecting and following patients with AP with infectious complications because PCT appears to be one of the best indicators of bacterial sepsis (7, 10 ) and a useful marker of the severity of infection (16 ) , although much remains to be understood about its role in normal physiology and in sepsis (17 ) . The possible role of PCT as a marker for biliary pancreatitis is still controversial. Rau et al. (8 ) found no correlation between the etiology of AP and PCT, whereas Brunkhorst et al. (9 ) reported that PCT may be an early marker of biliary pancreatitis. Our data, although based on a limited number of patients, are in agreement with the findings of Rau et al. (8 ) , indicating that PCT is an insensitive marker for the recognition of the biliary etiology of AP.
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